VENLO, Netherlands & WILMINGTON, DE — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) have announced a global collaboration to create a next-generation sequencing (NGS) diagnostic panel aimed at supporting innovative therapies for myeloproliferative neoplasms (MPNs). The effort will advance precision medicine by enabling targeted detection of genetic mutations critical to diagnosing and treating these rare blood cancers, including CALR-mutant conditions.
Under the agreement, QIAGEN will design and validate a multimodal panel using its NGS technology on the Illumina NextSeq 550Dx platform. This diagnostic tool will identify genomic alterations in hematological malignancies, particularly those driven by mutations in the CALR gene. The panel is intended to guide clinicians in selecting therapies, including INCA033989, a first-in-class monoclonal antibody developed by Incyte to target CALR-mutant cells in MPNs such as essential thrombocythemia (ET) and myelofibrosis (MF). Regulatory submissions and market preparations are planned for regions including the United States, Europe, and Asia-Pacific.
“Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with QIAGEN, which will facilitate CALR testing for patients with MPNs on a global basis,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development at Incyte. “The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF.”
MPNs are a group of blood cancers affecting bone marrow function, accounting for approximately 40% of hematological malignancies. Mutations in the CALR gene drive 25–35% of MPN cases, leading to abnormal blood cell production. Current treatment options are limited, primarily focusing on symptom management and prevention of complications. By delivering targeted diagnostics for mutCALR, this collaboration opens the door to more precise and effective treatment approaches.
“Together with Incyte, we are building a multimodal companion diagnostic using a powerful technology like next-generation sequencing to facilitate highly accurate testing for several blood cancer genes at once,” said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. “This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit.”
This collaboration reflects a broader focus on precision medicine, which aims to match treatments to the unique genetic and molecular characteristics of diseases. For patients with CALR-mutant MPNs, the combination of advanced diagnostics and targeted therapies like INCA033989 represents a significant step forward in improving clinical outcomes.
The partnership between QIAGEN and Incyte highlights the potential of integrating cutting-edge diagnostics and therapeutic innovation to transform the standard of care for rare and challenging diseases such as myeloproliferative neoplasms. With regulatory pathways underway, the collaboration sets a promising foundation for advancing science and patient care.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.